New depression drug NH102 begins human safety testing
NCT ID NCT07324408
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial tested the safety and tolerability of a new drug called NH102 in 40 healthy adults. Participants received either the drug or a placebo to check for side effects and how the drug moves through the body. The study is complete, but it does not yet test if NH102 works for depression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- NH102 (oral tablet)
- What this could lead to
- If successful, this could lead to a new treatment option for depression.
- What could go wrong
- This is a very early Phase 1 trial in healthy volunteers, not people with depression. It only tests safety and dosing, not whether the drug works for depression. Many drugs fail at this stage.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEPRESSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shanghai Mental Health Center
Shanghai, Shanghai Municipality, 201108, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your voice may hold clues to depression – a new device listens in
- Can a virtual meadow or a Mind's eye stream calm hospital anxiety?
- Could the sound of your voice reveal depression?
- Can MRI reveal the Brain's response to deep brain stimulation?
- Could a new drug offer hope for Treatment-Resistant depression?
- What did COVID-19 mean for family caregivers in zambia? a study seeks answers